GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Micro Biosystems Inc (NAS:RPID) » Definitions » Beneish M-Score

Rapid Micro Biosystems (Rapid Micro Biosystems) Beneish M-Score : -2.67 (As of May. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rapid Micro Biosystems Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.67 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Rapid Micro Biosystems's Beneish M-Score or its related term are showing as below:

RPID' s Beneish M-Score Range Over the Past 10 Years
Min: -3.39   Med: -2.2   Max: 7.91
Current: -2.67

During the past 5 years, the highest Beneish M-Score of Rapid Micro Biosystems was 7.91. The lowest was -3.39. And the median was -2.20.


Rapid Micro Biosystems Beneish M-Score Historical Data

The historical data trend for Rapid Micro Biosystems's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Micro Biosystems Beneish M-Score Chart

Rapid Micro Biosystems Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - -0.40 -2.13 -2.48

Rapid Micro Biosystems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.26 -3.39 -3.08 -2.48 -2.67

Competitive Comparison of Rapid Micro Biosystems's Beneish M-Score

For the Medical Devices subindustry, Rapid Micro Biosystems's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Micro Biosystems's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Rapid Micro Biosystems's Beneish M-Score falls into.



Rapid Micro Biosystems Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Rapid Micro Biosystems for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7417+0.528 * 2.066+0.404 * 0.0552+0.892 * 1.2825+0.115 * 0.8966
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6882+4.679 * -0.0617-0.327 * 1.4169
=-2.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $5.35 Mil.
Revenue was 5.611 + 6.337 + 6.145 + 5.002 = $23.10 Mil.
Gross Profit was -1.523 + -0.172 + -1.631 + -1.892 = $-5.22 Mil.
Total Current Assets was $108.16 Mil.
Total Assets was $127.73 Mil.
Property, Plant and Equipment(Net PPE) was $18.60 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.15 Mil.
Selling, General, & Admin. Expense(SGA) was $37.24 Mil.
Total Current Liabilities was $15.60 Mil.
Long-Term Debt & Capital Lease Obligation was $5.92 Mil.
Net Income was -13.322 + -11.172 + -13.392 + -14.016 = $-51.90 Mil.
Non Operating Income was -0.029 + -0.017 + -0.026 + -0.029 = $-0.10 Mil.
Cash Flow from Operations was -15.525 + -9.497 + -9.708 + -9.19 = $-43.92 Mil.
Total Receivables was $5.62 Mil.
Revenue was 5.035 + 4.374 + 4.739 + 3.86 = $18.01 Mil.
Gross Profit was -1.79 + -2.601 + -2.794 + -1.221 = $-8.41 Mil.
Total Current Assets was $129.15 Mil.
Total Assets was $173.28 Mil.
Property, Plant and Equipment(Net PPE) was $20.33 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.04 Mil.
Selling, General, & Admin. Expense(SGA) was $42.19 Mil.
Total Current Liabilities was $13.66 Mil.
Long-Term Debt & Capital Lease Obligation was $6.94 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(5.348 / 23.095) / (5.622 / 18.008)
=0.231565 / 0.312195
=0.7417

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-8.406 / 18.008) / (-5.218 / 23.095)
=-0.466793 / -0.225936
=2.066

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (108.16 + 18.603) / 127.731) / (1 - (129.145 + 20.334) / 173.281)
=0.007578 / 0.137361
=0.0552

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=23.095 / 18.008
=1.2825

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.036 / (3.036 + 20.334)) / (3.152 / (3.152 + 18.603))
=0.12991 / 0.144886
=0.8966

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(37.237 / 23.095) / (42.192 / 18.008)
=1.61234 / 2.342959
=0.6882

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5.916 + 15.6) / 127.731) / ((6.94 + 13.66) / 173.281)
=0.168448 / 0.118882
=1.4169

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-51.902 - -0.101 - -43.92) / 127.731
=-0.0617

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Rapid Micro Biosystems has a M-score of -2.67 suggests that the company is unlikely to be a manipulator.


Rapid Micro Biosystems Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Rapid Micro Biosystems's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Micro Biosystems (Rapid Micro Biosystems) Business Description

Traded in Other Exchanges
N/A
Address
1001 Pawtucket Boulevard West, Suite 280, Lowell, MA, USA, 01854
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Executives
Sean M Wirtjes officer: Chief Financial Officer C/O VARIAN, INC., 3120 HANSEN WAY, M/S D-083, PALO ALTO CA 94304-1030
Spignesi Robert G. Jr. director, officer: President and CEO C/O RAPID MICRO BIOSYSTEMS, INC., 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kennedy Lewis Capital Partners Master Fund Ii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Klm Gp Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Capital Partners Master Fund Iii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Iii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Investment Holdings Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Investment Management Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Management Lp 10 percent owner 225 LIBERTY STREET, SUITE 4210, NEW YORK NY 10281
David Chene 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Darren Richman 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Inese Lowenstein director C/O RAPID MICRO BIOSYSTEMS INC, 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854
Richard A Keys officer: CHIEF COMMERCIAL OFFICER C/O RAPID MICRO BIOSYSTEMS INC, 1001 PAWTUCKET BOULEVARD, SUITE 280, LOWELL MA 01854